title: Nevirapine toxicity in a cohort of HIV-1-infected pregnant women.
abstract: OBJECTIVE
  The purpose of this study was to complete an evaluation of nevirapine (NVP) toxicity in a cohort of HIV+ pregnant women.
  
  
  METHODS
  This was a retrospective study of 611 women followed from January 1996 to December 2003. All women who used NVP for > 7 days were included. Multivariate logistic regression was used to test independent association of CD4 and hepatitis C virus (HCV) infection related to the outcome of toxic effects of NVP.
  
  
  RESULTS
  One hundred ninety-seven women were exposed to NVP for > 7 days, and toxicity occurred in 11 (5.6%), leading to drug discontinuation in 7 patients. One case of Stevens-Johnson syndrome occurred. No serious liver toxicity occurred except for 1 grade 4 cholestasis. Median CD4 was 344 in women without toxicities and 298 in women with toxicities. HCV was the only significant factor associated to toxicity by logistic regression (odds ratio [OR] 15.61, P = .001).
  
  
  CONCLUSIONS
  NVP toxicities occurred in a very small fraction of patients and were not associated with fatalities.
authors.affiliation: Department of Infectious Diseases, Hospital dos Servidores do Estado, Rio de Janeiro, RJ, Brazil. esau@uninet.com.br
authors.forename: Esau Custódio
authors.initials: EC
authors.lastname: João
authors.forename: Guilherme A
authors.initials: GA
authors.lastname: Calvet
authors.forename: Jacqueline A
authors.initials: JA
authors.lastname: Menezes
authors.forename: Marcos M
authors.initials: MM
authors.lastname: D'Ippolito
authors.forename: Maria Letícia S
authors.initials: ML
authors.lastname: Cruz
authors.forename: Luisa Andrea T
authors.initials: LA
authors.lastname: Salgado
authors.forename: Haroldo J
authors.initials: HJ
authors.lastname: Matos
mesh_terms: D000328:Adult; D019380:Anti-HIV Agents / Q000009:adverse effects* / Q000097:blood / Q000627:therapeutic use; D018791:CD4 Lymphocyte Count; D002779:Cholestasis / Q000139:chemically induced; D015331:Cohort Studies; D005260:Female; D015658:HIV Infections / Q000097:blood / Q000150:complications / Q000188:drug therapy*; D006509:Hepatitis B / Q000150:complications; D006526:Hepatitis C / Q000150:complications; D006801:Humans; D019829:Nevirapine / Q000009:adverse effects* / Q000627:therapeutic use; D011247:Pregnancy; D011251:Pregnancy Complications, Infectious / Q000188:drug therapy*; D012189:Retrospective Studies; D013262:Stevens-Johnson Syndrome / Q000139:chemically induced
chemical_list: D019380:Anti-HIV Agents; D019829:Nevirapine